Spero Therapeutics, Inc.
NASDAQ:SPROBiotechnology
+$0.08 today
- Market cap
- $50.92M
- Beta
- 1.46
- P/E (TTM)
- 8.2
- EPS (TTM)
- $0.27
Volume 0.27M
Average 0.78M
SPRO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Spero Therapeutics, Inc.NASDAQ: SPRO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $7.2M (cash outflow) fell 48.1% year over year, behind the +121.8% change in trailing-twelve-month net income.
Context
- Net income amounted to 14.4% of revenue in FY2025, down 128.5 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$74.7M (-971.4%) for the fiscal year ending Dec 2026, a slowdown from the +112.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.2M-122.9% QoQ
- Last fiscal yearDec 2025
- $8.57M+112.5% YoY
- LTMMar 2026
- $15.24M+121.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -48.1% | +479.7% | +527.7 pp |
| 1 year | +112.5% | -971.4% | -1083.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 8.57M USD
- Year-over-year change
- +112.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.57M | +112.5% |
| FY2024 | 2024-12-31 | (68.57M) | -400.6% |
| FY2023 | 2023-12-31 | 22.81M | +149.1% |
| FY2022 | 2022-12-31 | (46.42M) | +48.3% |
| FY2021 | 2021-12-31 | (89.76M) | — |
Net Income vs competitors
How SPRO compares with its peers on the latest reported figures
- SPRO's LTM Mar 2026 net income of $15.24M is the smallest of the 10 companies compared; the peer median is $70.49M.
- Its year-over-year change of +121.8% is the highest of 9, against a peer median of -13.4%.
- Net income amounts to 27.8% of revenue for SPRO, versus a peer median of 892.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $113.28M | -2.6% | +41.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $84.93M | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $84.53M | +68.1% | +22.9% | — | |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $46.9M | -164.3% | — | 4088.8% | |
| LTM Mar 2026 | $30.92M | — | +47.5% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.54M | -14.9% | +3.3% | — |
| LTM Mar 2026 | $19.58M | -41.2% | +3.2% | — | |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| Peer median (excluding SPRO) | $70.49M | -13.4% | +3.3% | 892.4% | |
Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (89.76M) | (46.42M) | 22.81M | (68.57M) | 8.57M |
| Depreciation & Amortization | 1.12M | 869K | 367K | 2K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.43M | 9.12M | 7.93M | 7.79M | 4.33M |
| Change in Working Capital | 12.86M | 22.09M | (70.38M) | 36.28M | (27.16M) |
| Accounts Receivables | 3.83M | 1.55M | (461K) | (1.54M) | 3.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (53K) | (484K) | 761K | 5.93M | (6.61M) |
| Other Working Capital | 9.08M | 21.02M | (70.68M) | 31.9M | (23.6M) |
| Other Non-Cash Items | 11.43M | 6.61M | 6.28M | 1.04M | 1.64M |
| Operating Cash Flow | (64.35M) | (7.73M) | (33M) | (23.44M) | (12.62M) |
| Capital Expenditures | 64.35M | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 39K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (43.92M) | (26.97M) | 0 | 0 | 0 |
| Sales of Investments | 51.55M | 60.78M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 7.67M | 33.81M | 0 | 0 | 0 |
| Debt Repayment | 47.48M | (54.49M) | 0 | 0 | 0 |
| Common Stock Issued | 36.57M | 24.93M | 221K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 84.05M | (29.55M) | 221K | 0 | 0 |
| Effect of Forex Changes | (1) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 27.38M | (3.48M) | (32.77M) | (23.44M) | (12.62M) |
| Free Cash Flow | (64.35M) | (7.73M) | (33M) | (23.44M) | (12.62M) |
Spero Therapeutics, Inc.
NASDAQ:SPRO
Intrinsic Alpha fair value
Locked
Current Price
$0.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.